Pharmaceutical Giants Battle with Legislatures Over Biologic Drugs

Aug 08, 2013

USAToday.com

In state after state, makers of brand-name biologic drugs, led by the pharmaceutical giants Amgen and Genentech, have been unable to convince state legislatures to require pharmacists to notify doctors (and sometimes patients) when they substitute generics for brand-name drugs. Manufacturers of copies fiercely opposed such a requirement, which they said would put them at a competitive disadvantage.

Notification measures died in Arizona, Arkansas, Colorado, Indiana, Illinois, Maryland, Mississippi, Nevada, Texas and Washington. Oregon, Utah and Virginia all adopted notification requirements, but with sunsetting provisions that will take effect before any of the knock-offs reach the market. 

Only one state, North Dakota, passed the measure the brand-name manufacturers sought. Read more

Join the discussion

We welcome your thoughtful comments. Please comply with our Community rules.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments